Con este acuerdo, la biofarmacéutica española AbilityPharma inicia la fabricación de su fármaco principal ABTL0812 para administrar a pacientes con cáncer de páncreas en el marco del ensayo clí...
Read moreThe core idea of Open innovation is that companies leverage the ideas and resources of external actors such as customers, suppliers, universities, start-ups, etc.
Read moreOryzon suma su apoyo a la lucha contra la mortalidad infantil y contribuye al ODS 3 relativo a salud y bienestar promovido por las Naciones Unidas
Read moreStrategic alliances are crucial for success in the global pharma market. By forming partnerships, companies can access complementary capabilities, share risks, enhance market access, and leverage shar...
Read moreProducts & Technology, a Rubió Group company, has undertaken research and development (R&D) to create a medication aimed at treating insomnia in children with Attention Deficit Hyperactivity Disorder...
Read moreResearchers at IBEC has just published a work describing a new bioink designed for engineering human skin constructs using norbornene-pullulan-based hydrogels.
Read moreEsta alianza se fundamenta en la especificidad del producto ya que se trata de un secretoma selectivo, un producto nuevo a nivel industrial para el que no hay todavía plantas en España para su fabri...
Read moreR&D investments of € 4.6 million were made, of which € 4.2 million in development and € 0.4 million in research. Following the completion of the PORTICO clinical trial, the R&D investment intens...
Read moreEl Instituto de Tecnología Química sintetiza por primera vez una zeolita enantiomórficamente pura, un material clave en la industria química para la producción selectiva de productos farmacéutic...
Read moreResearchers at the Clínic-IDIBAPS have prepared a review article on the biology, mechanism of action, pharmacology and toxicology of lithium.
Read moreOryzon Genomics announced today that its management will give an update on corporate progress at several international events in September.
Read moreOryzon Genomics, S.A. announced today that it has received additional “Decision to grant” communications for important patents relating vafidemstat, Oryzon’s LSD1 inhibitor in clinical developme...
Read more